1 / 6

ACUITY: Death, MI, revascularization for ischemia, or major bleeding by 30 days

15. 11.8. 11.7. 10.1. 10. 5. 0. ACUITY: Death, MI, revascularization for ischemia, or major bleeding by 30 days. %. Heparin + GPI IIb/IIIa. Bivalirudin + GPI IIb/IIIa. Bivalirudin alone. p = 0.015 for superiority of bivalrudin alone vs. hep+GPI

gerd
Download Presentation

ACUITY: Death, MI, revascularization for ischemia, or major bleeding by 30 days

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 15 11.8 11.7 10.1 10 5 0 ACUITY: Death, MI, revascularizationfor ischemia, or major bleeding by 30 days % Heparin + GPI IIb/IIIa Bivalirudin + GPI IIb/IIIa Bivalirudin alone p = 0.015 for superiority of bivalrudin alone vs. hep+GPI p < 0.001 for non-inferiority of hep+GPI vs. bival+GPI Stone GW, et al. N Engl J Med 2006;355:2203-16.

  2. Primary Endpoint Measures (ITT) — 30 DaysUFH/Enoxaparin + GPI vs. Bivalirudin Alone GPI = glycoprotein IIb/IIIa inhibitor; ITT = intention to treat; UFH = unfractionated heparin. Presented at ACC.07 and Stone GW et al. N Engl J Med 2006;355:2203-16.

  3. Kaplan-Meier Curves for Mortalityin Patients With or Without Major Bleeding Manoukian S et al. J Am Coll Cardiol 2007;49:1362-8.

  4. ACUITY Trial Treatment Strategy UFH = unfractionated heparin; GPI = glycoprotein IIb/IIIa inhibitor; PCI = percutaneous coronary intervention; CABG = coronary artery bypass graft. Stone GW et al. N Engl J Med 2006;355:2203-16.

  5. 1-Year ACUITY Trial ResultsPCI Cohort ACS = acute coronary syndrome; GP = glycoprotein; LOS = length of stay; PCI = percutaneous coronary intervention.

  6. 1-Year ACUITY Trial Conclusion These results suggest bivalirudin monotherapy should be the preferred adjunctive antithrombotic strategy in moderate- and high-risk acute coronary syndrome patients undergoing percutaneous coronary intervention and add to the evidence on the relationship between early bleeding and long-term outcome.

More Related